It has been clinically noticed that the pancreatic lipase inhibitor orlistat has a beneficial approved effect on obesity and hyperlipidemia by increasing fat excretion through the feces and by inhibiting pancreatic lipase [46]. Here, PNLIP is linked to obesity due to melanocortin 4 receptor deficiency.